This websiteโs original language is English. For translation, click the globe icon or choose Translate in the menu.
6 matching records found
Hong Kong biotech entrepreneur Ricky Chiu Yin-to is seeking to make cervical cancer screening easier through urine-based HPV testing, using sample-concentration technology developed by his company. His company, Phase Scientific, made its name during the Covid-19 pandemic through its rapid antigen test, Indicaid. The product received US emergency-use authorisation in July 2021, was used in Hong Kong community testing and sold in more than 30 countries. At the start of the pandemic, the firm...
Novartis AG will license a messenger RNA-based autoimmune therapy from Chinaโs Abogen Biosciences, in a deal worth as much as $7.8 billion.
Hong Kong can attract more global biotech investments if the city builds up a new healthcare financial model, according to AstraZeneca, a Cambridge-based multinational pharmaceutical giant. While global drug makers have been doubling down on investments in mainland China in recent years, AstraZeneca brought over 60 clinical trials to the city and invested over HK$200 million (US$25.5 million) over the past three years. Hong Kong was still a key research and development hub for the firm, David...
Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firmโs flagship cancer drug, while a new deal from US giant Merck further underscored the sectorโs global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akesoโs immunotherapy drug ivonescimab outside China. Summit and AstraZeneca would...